Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
University of Cincinnati
University of Cincinnati
Janssen Research & Development, LLC
Genmab
Mayo Clinic
Neonc Technologies, Inc.
University of California, Davis
Washington University School of Medicine
Inhibrx Biosciences, Inc
M.D. Anderson Cancer Center
VM Oncology, LLC
Roswell Park Cancer Institute
Dragonfly Therapeutics
ImmVira Pharma Co. Ltd
Scancell Ltd
Hookipa Biotech GmbH
Taipei Veterans General Hospital, Taiwan
NuCana plc
National Institutes of Health Clinical Center (CC)
Medicenna Therapeutics, Inc.
Rakuten Medical, Inc.
University of Cincinnati
Mural Oncology, Inc
M.D. Anderson Cancer Center
Rapa Therapeutics LLC
Precision Biologics, Inc
TiumBio Co., Ltd.
Alentis Therapeutics AG
Merus B.V.
RAPT Therapeutics, Inc.
Vaccinex Inc.
CJ Bioscience, Inc.
Nykode Therapeutics ASA
University of Washington
Simcha IL-18, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
Evopoint Biosciences Inc.
Icahn School of Medicine at Mount Sinai
SecuraBio
Sensei Biotherapeutics, Inc.
Genocea Biosciences, Inc.
Silverback Therapeutics
Dynavax Technologies Corporation
Incyte Corporation
Incyte Corporation
Daiichi Sankyo